Minister of Health’s Decision that JAMP is not a “Second Person” Was Reasonable

In its new drug submission for SIMLANDI, a biosimilar containing adalimumab, JAMP Pharma Corporation (“JAMP”) sought approval for three specific presentations: (i) 40 mg/0.4 mL pre-filled syringe; (ii) 40 mg/0.4 mL auto-injector pen; and (iii) 80 mg/0.8 mL pre-filled syringe.
Given that AbbVie did not market the equivalent presentations of HUMIRA (adalimumab) in Canada, in a comprehensive and detailed decision, the Minister of Health (the “Minister”) determined that JAMP was not a “second person” for purposes of subsection 5(1) of the Patented Medicines (Notice of Compliance) Regulations (the “PM(NOC) Regulations”) and was thus not required to address patents listed on the patent register by AbbVie before being issued a Notice of Compliance (“NOC”).
Subsequently, the Minister issued an NOC to JAMP for its three presentations of SIMLANDI.
In AbbVie Corporation et al. v. The Minister of Health and JAMP Pharma Corporation, 2022 FC 1209, Justice Fothergill of the Federal Court dismissed AbbVie’s applications to judicially review the Minister’s decisions, on the basis that the Minister’s decisions were reasonable.
Justice Fothergill observed that the “PM(NOC) Regulations are closely connected with the Minister’s functions, and the Minister has great expertise in their application and interpretation”.
In summary, Justice Fothergill determined that the “Minister’s interpretation of s 5(1) of the PM(NOC) Regulations as applying only to a version of a drug that has a specific drug identification number [DIN] and that is marketed in Canada was reasonable, particularly considering the statutory objective of providing a patent enforcement mechanism only in relation to products that are in fact available to Canadians”.
Authors
Expertise
Insights
-
Intellectual Property Litigation
Carrot Puff Copycat: Copyright Infringed in Federal Court of Australia Case
As reported by Mason Hayes & Curran, the Federal Court of Australia has reportedly found the supermarket chain, Aldi, liable for copyright infringement regarding illustrations used on the… -
Intellectual Property Litigation
Carnegie Hall Takes Trademark Center Stage in Legal Battle
Carnegie Hall has reportedly commenced an action against Carnegie Diner and Café for trademark infringement.In its complaint filed with the United States District Court, Southern District of New York… -
Intellectual Property Litigation
Federal Court of Appeal Reiterates Permissive Approach to Granting Leave to Amend Defective Pleadings
In Bell Canada et al. v. Millennium Funding, Inc. et al., 2025 FCA 153, Bell Canada and Bell Aliant (collectively, “Bell”) appealed an order granting the Respondents’ (collectively, “Millenium… -
Intellectual Property Litigation
Under the Radar, Over the Counter: Goyard's Quiet Battle Against Fake Luxury
Goyard, the Parisian brand established in 1853 and still privately owned, has reportedly faced a surge in counterfeit bags flooding the market. The company refrains from advertising, avoids e-commerce… -
Intellectual Property Litigation
Music to Sheeran’s Ears: Supreme Court Declines to Rehear Marvin Gaye Copyright Suit
The US Supreme Court has declined to revisit a copyright dispute over alleged similarities between Ed Sheeran’s 2014 hit, “Thinking Out Loud”, and Marvin Gaye’s 1973 classic, “Let’s Get It On… -
Intellectual Property Litigation
Federal Court Reaffirms Importance of Viva Voce Testimony
In McCain Foods Limited v. J.R. Simplot Company 2024 FC 1729, the Federal Court considered the circumstances in which an examination for discovery of a person, other than a person examined under Rule…